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Background. p-cresol, which is extensively metabolized into
p-cresylglucuronide in the rat, is related to several biochemical
and physiologic alterations in uremia and is not removed ade-
quately by current hemodialysis strategies. The knowledge of
its in vivo kinetic behavior could be helpful to improve the
current removal strategies.
Methods. We investigated the kinetic behavior of intrave-
nously injected p-cresol (10 mg/kg) in rats with normal and
decreased renal function, and compared the results with those
obtained for creatinine (60 mg/kg) under similar conditions.
Renal failure was obtained by 5/6 nephrectomy. Both p-cresol
and p-cresylglucuronide were analyzed using reversed-phase
high-performance liquid chromatography (RP-HPLC). The re-
lation between the p-cresylglucuronide peak height and the
underlying amount of p-cresol was determined after hydrolysis
of the glucuronide with -glucuronidase. We calculated urinary
excretion of p-cresol with and without taking p-cresylglucuro-
nide into account. In addition, total, renal, and non-renal clear-
ance, half-life, and volume of distribution were calculated for
p-cresol.
Results. Over a 4-hour period, p-cresol serum concentration
showed only a minimal decline in rats with decreased renal
function (t1/2 11.7 0.4 hours), compared to rats with normal
renal function (t1/2  1.4  0.7 hours). A similar observation
was made for p-cresylglucuronide. In rats with normal renal
function, 21.0  10.0% of the injected p-cresol was excreted
in urine as p-cresol and 60.7  25.0% as p-cresylglucuronide;
in rats with renal failure, the respective amounts were 6.7 
7.5% and 32.0  25.3% (P  0.05 vs. normal renal function)
(total recovery 81.81  31.07% vs. 38.50  32.09%, P  0.05).
The volume of distribution of p-cresol was approximately 4
times larger than that of creatinine, but was not significantly
affected by renal failure. Not only renal, but also non-renal
and total clearance, were much lower in rats with decreased
renal function.
Conclusion. The present data sheds a light on the kinetic
behavior of p-cresol in uremic patients; the large volume of
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distribution, especially, might explain the inadequate dialy-
tic removal of p-cresol. In addition, a substantial amount of
p-cresol is removed by metabolism, and both renal and non-
renal clearance are disturbed in uremia.
Uremia is characterized by a gradual accumulation of
several compounds, in part originating from the degrada-
tion of proteins and amino acids [1–7]. One of these
compounds, p-cresol (molecular weight 108.1 D), has
lipophilic properties and is mainly generated by anaero-
bic intestinal bacteria as an end product of the biotrans-
formation of tyrosine [3, 8–12]. Several in vitro and in
vivo studies in humans and animals have reported ele-
vated serum concentrations of p-cresol in renal failure
[1, 3–7, 13, 14]. With a serum protein binding of 99%
in healthy subjects, and approximately 90% in uremic
patients [4], this solute might be considered a prototype
of the protein-bound uremic retention solutes. Further-
more, recent data suggest that lipophilic and/or protein-
bound substances could be the cause of several biologic
and physiologic alterations in uremia [6, 13, 15–21]. In
fact, the toxic effect of p-cresol on vital biochemical func-
tions such as the phagocytic function has already repeat-
edly been demonstrated [5, 16, 22, 23]. Other biochemi-
cal and physiologic defects in the presence of p-cresol
have also been reported [5, 6, 13, 15, 24, 25] and recently,
it was also demonstrated that p-cresol inhibits the adhe-
sion of leukocytes on the endothelium, thus affecting the
body defense mechanism [26].
The question might be raised whether an adequate
removal of p-cresol during hemodialysis would improve
the outcome of dialysis patients. However, we have re-
cently demonstrated that p-cresol is removed only to a
limited extent by both low- and high-flux dialysis [7]. To
obtain an efficient removal of p-cresol, as well as of other
protein-bound retention solutes, it is important to collect
information on the in vivo kinetic characteristics of these
compounds.
To our knowledge, the kinetic characteristics of p-cresol
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have not yet been investigated in uremic conditions.
Therefore, we set out to study the kinetic parameters of
this compound after its injection in rats with decreased
renal function, and to compare the results with those
obtained in rats with normal renal function, as well as
with those obtained for creatinine under similar condi-
tions. Furthermore, in previous experiments in rats with
normal renal function, p-cresylglucuronide had been
identified as the main metabolite of p-cresol [27]. Hence,
we also studied the appearance of p-cresylglucuronide
in the present set-up together with its impact on the
kinetic characteristics.
METHODS
Materials
All chemical reagents were of analytical grade and
were purchased from VWR (Leuven, Belgium), Analis
(Namur, Belgium), Acros Organics (Geel, Belgium), BDH
Laboratory Supplies (Poole, UK) or Sigma Chemical
Co. (St. Louis, MO, USA). Needles and syringes were
purchased from Becton Dickinson (Erembodegem, Bel-
gium), and polyethylene (PE) tubings from Medihac (St.
Michielsgestel, The Netherlands). Ketalar was obtained
from Warner Lambert (Dublin, Ireland), Fluothane from
Zeneca (Destelbergen, Belgium), and Nembutal from
Sanofi (Brussels, Belgium). Liquid nitrogen was deliv-
ered by Air Liquide (Aalter, Belgium), isotonic saline
solution by Baxter (Lessines, Belgium), and heparin by
B Braun Pharma (Diegem, Belgium). -Glucuronidase
was obtained from Sigma Chemical Co.
Nephrectomy
Male OFA rats (Iffa Credo; Charles River,Wilming-
ton, MA, USA) weighing approximately 300 g were sub-
mitted to 5/6 renal ablation [5/6 nephrectomy (Nx)]. The
procedure was spread over two interventions with an
interval of one week, wherein the animals were each
time anaesthetized using Ketalar intraperitoneally (0.5
mL, 50 mg/mL). During the first intervention, the right
kidney was exposed through a dorso-lateral incision and
subsequently separated from the adrenal gland. After
clamping the kidney vessels, both poles of the kidney,
as well as the anterior and posterior sides, were infarcted
by freezing them for one minute using a copper bar that
had been submersed in liquid nitrogen. Subsequently,
the vessel clamp was removed and the wound was closed.
During the second intervention, the left kidney was ex-
posed as mentioned above. All afferent and efferent
vessels were clamped using surgical clips, followed by a
total resection of the kidney.
During the entire period preceding and following the
interventions, as well as during the interval between the
two interventions, rats were maintained on a standard
diet with free access to water and food (standard mainte-
nance chow; Pavan Service-Carfil, Oud-Turnhout, Bel-
gium). The degree of renal failure of the animals was
evaluated by assessing the serum creatinine and urea
concentrations. Blood was withdrawn weekly from the
tail artery under a light Fluothane anesthesia. Four to
five weeks after the second intervention, rats reached a
stable uremic condition (serum creatinine concentration
10.0 mg/L or serum urea concentration 1000 mg/L)
and were submitted to the experiment.
Animal preparation
The animals were prepared for the experiment as de-
scribed previously [28]. In brief, rats were anesthetized
with an intraperitoneal injection of 60 mg/kg Na-pento-
barbital (Nembutal) and positioned on a heating path
at 37C. Subsequently, the trachea was intubated with a
PE240 tube [inner diameter (ID), 1.67 mm; outer diam-
eter (OD), 2.42 mm). The left jugular vein and carotid
artery were catheterized with PE50 tubes (ID, 0.58 mm;
OD, 0.97 mm) filled with a heparin solution (250 IU/mL)
to prevent clotting. The urinary bladder was exposed
through a ventral incision, all present urine was collected,
and a PE160 tube (ID, 1.14 mm; OD, 1.57 mm) was in-
serted for the periodic urine collection.
Study design
Twenty-two rats with decreased renal function were
randomly allocated to: (1) a control group that received
a bolus of isotonic saline (N 7); (2) a group that received
a bolus of a creatinine solution (60 mg/kg) (N  7); and
(3) a group that received a bolus of a p-cresol solution
(10 mg/kg) (N  8). Both creatinine and p-cresol were
dissolved in isotonic saline. To compare p-cresol and
creatinine kinetics in rats with normal and decreased
renal function, 9 rats with normal renal function were
also injected with a bolus of the p-cresol solution and
another 8 rats were injected with a bolus of the creatinine
solution.
After an intravenous injection of 1.5 mL of an isotonic
saline solution and a 30 minute equilibration period,
each animal received the bolus of p-cresol, creatinine, or
isotonic saline (1.5 mL) according to the group allocation
described above. The administered amounts of p-cresol
and creatinine were determined in a way that 5 minutes
after injection, total serum concentrations could be ex-
pected to be similar to those observed in uremic patients
(5.4 to 12.0 mg/L for p-cresol and 78.9 to 113.0 mg/L for
creatinine) [4, 7, 29–31]. Immediately after injection of
the bolus, a maintenance isotonic saline infusion con-
taining Nembutal (600 mg/L) was started at a constant
rate of 0.72 mL/h (7.2 	g/min).
Blood samples (0.7 mL) were withdrawn from the
carotid artery immediately before the injection of the
bolus and 5, 30, 60, 120, 180, and 240 minutes after its
injection. Prior to each blood collection, the catheter
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was flushed back and forth with the heparin solution,
and the first 3 drops of blood were discarded. Blood
samples were immediately centrifuged and serum was
transferred into another cup. Immediately following the
bolus injection, urine collection was started at 1-hour
intervals. After centrifugation of the urine samples, the
supernatant was transferred into another cup and vol-
ume was assessed. All samples were kept at 
20C until
analysis. At the end of the experiment, rats were sacri-
ficed by injection of an overdose of Nembutal (100 mg/kg
body weight). All experiments were in accordance with
the guiding principles for the use of animals in toxicology
and were approved by the Hospital’s Ethics Review
Committee for laboratory animals.
Assay of p-cresol and p-cresylglucuronide
Peak heights of p-cresol in serum and urine samples
were determined using reverse-phase high-performance
liquid chromatography (RP-HPLC) as previously de-
scribed [4]. In brief, 100 	L samples were first depro-
teinized using HCl (6 mol/L), thereby releasing intact
p-cresol from serum proteins, after which p-cresol was
extracted with isopropyl ether. After addition of metha-
nolic NaOH (0.05 mol/L) and the internal standard (IS),
methanol, and isopropyl ether were evaporated in a vac-
uum centrifuge (RC 10.22; Jouan, Saint-Herblain, France).
The dry residue was then redissolved in HCl (0.05 mol/L)
and analyzed on a RP C18 column (4.6  150 mm with
5 	m particles; Beckman Instruments, Fullerton, CA,
USA) with a 50	L loop, coupled to a fluorescence detec-
tor (RF 530; Shimadzu, Tokyo, Japan) at excitation/emis-
sion wavelengths of 284/310 nm. Methanol and a 50
mmol/L ammonium formate buffer (pH 3.0) were used
as mobile phase using a linear gradient (from 45 to 75%
methanol in 10 minutes and then to 100% methanol at
minute 12) at a flow rate of 1 mL/min. To calculate the
concentration of p-cresol, a calibration curve [peak height
ratio p-cresol/IS versus p-cresol concentration] was made
from standard solutions from a stock solution containing
32 mg/L. Accuracy and precision of the method was
tested as previously described [4].
In a previous study, we demonstrated that, apart from
p-cresol, an additional peak (which was identified as p-cres-
ylglucuronide) appeared in these HPLC runs; whenever
present, this glucuronide was completely extracted by
the presently applied method [27]. Therefore, during the
same HPLC run, the peak height of p-cresylglucuronide
was also determined.
Assay of creatinine
Creatinine concentrations in serum and in urine were
analyzed using the Jaffe´ method on a Creatinine ana-
lyzer 2 (Beckman Instruments).
Urinary excretion
The urinary excretion of p-cresol and creatinine (Aurine)
was calculated as the sum of the individual amounts (mg)
recovered in each of the 4 1-hour fractions. The same
calculation was then repeated for p-cresylglucuronide.
However, since p-cresylglucuronide is not commercially
available, we were not able to construct a calibration
curve for this compound. We therefore expressed its
concentration as equivalent amounts of p-cresol after
hydrolysis of p-cresylglucuronide into its parent com-
pound p-cresol, as previously described [22].
For that purpose, the urine fractions were pooled per
experimental group and per 1-hour fraction, respecting
the ratios of the respective collection volumes in the
different rats. A linear regression analysis (Spearman)
was made between the peak heights of p-cresylglucuro-
nide before enzyme treatment and the increase of the
p-cresol peaks after the enzyme treatment for all experi-
mental data obtained in a dose response experiment
(750, 1000, 1500, and 2000 U of -glucuronidase added).
Urine samples were 1:9 diluted with acetate buffer (0.07
mol/L, pH 5.0), followed by the addition of -glucuroni-
dase (Type H-3 from Helix pomatia; 119,000 U/mL) or
an equivalent volume of isotonic saline solution (con-
trol), and a 60 minute incubation at 37C. Analyses were
done in triplicate. After incubation, samples were pre-
pared for HPLC analysis as described above and ana-
lyzed by RP-HPLC.
The percentage of the administered dose that was re-
covered in the urine was calculated from
Aurine
Dose
 100.
Kinetic analysis of the data
For p-cresol and creatinine, the elimination rate con-
stant (K), half-life (t1/2), area under the concentration
time curve (AUC), total clearance (CLt), renal clearance
(CLr), and volume of distribution (Vd) were estimated
as previously described [28]. Non-renal clearance was
determined as CLt 
 CLr.
For each rat, K was determined as the slope of the
regression line, calculated on the terminal points of the
log concentration time course (120, 180, and 240 min-
utes). T1/2 was then calculated from
0.693
K
. The AUC up
to minute 240 (AUC0-240) was calculated by the trapezoi-
dal rule and the remaining AUC, from minute 240 to
infinity (AUC240-∞), was calculated by
C240
K
, with C240 the
concentration in the sample taken at minute 240. Subse-
quently, AUC0-∞ was determined as AUC0-240AUC240-∞.
CLt was calculated from
Dose
AUC0-∞
and CLr from
Aurine
AUC0-240
.
Vd was calculated from
CLt
K
. CLt, CLr, and Vd were nor-
malized for body weight.
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Table 1. Baseline characteristics (before administration of creatinine or p-cresol)
Creatinine-treated group p-cresol–treated group
Normal renal function Decreased renal function Normal renal function Decreased renal function
(N  8) (N  7) (N  9) (N  8)
Body weight g 3169 36011a 31611 33269
Serum creatinine mg/L 32 132a 31 178a
Serum p-cresol mg/L DL 0.4150.187a DL 0.4880.567a
Hematocrit % 462 365a 444 293a
a P  0.05 vs. normal renal function; DL, detection limit, 0.002 mg/L
In serum and urine samples both, endogenous peak
heights were subtracted from the measured peaks prior
to the calculation of the kinetic parameters.
Statistical analyses
Results are presented as mean  SD. The 3 groups
of rats with decreased renal function were compared
by a non-parametric Kruskal-Wallis analysis of variance
(ANOVA). If a significant difference was reached, an
unpaired Mann-Whitney U test was used to test the dif-
ference between each pair of groups. The latter test was
also used when comparisons were made with rats with
normal renal function. Significance was assumed when
P  0.05.
RESULTS
Serum concentration time course
Table 1 shows the baseline characteristics for the ex-
perimental rats prior to the administration of p-cresol
or creatinine. In rats with normal and decreased renal
function both, serum creatinine and p-cresol reached
similar levels in the groups receiving creatinine and
p-cresol. As expected, the highest creatinine and p-cresol
serum concentrations were observed in rats with de-
creased renal function (P  0.05). Serum concentrations
of both compounds remained stable throughout the ex-
periment in rats that received only isotonic saline solu-
tion (data not shown).
In rats with normal and decreased renal function both,
creatinine and p-cresol serum concentrations gradually
declined from the value observed 5 minutes after its
administration (Fig. 1). However, the decline was much
slower in animals with decreased renal function, resulting
in higher serum levels from minute 30 onward compared
to animals with normal renal function (P  0.05).
We described earlier that after the injection of p-cre-
sol, an additional chromatographic peak appeared next
to that of p-cresol in serum and urine samples [28]. In
a recent study, we demonstrated that this peak represents
p-cresylglucuronide [27]. The peak height of this com-
pound 5 minutes after the injection of p-cresol reached
similar values in serum of rats with normal and decreased
renal function (959  433 and 1096  338 fluorescence
Fig. 1. Serum concentration time course of creatinine (A ) and p-cresol
(B ) in rats with normal () and decreased () renal function after
intravenous injection of creatinine (60 mg/kg) or p-cresol (10 mg/kg).
*P  0.05 vs. normal renal function.
Fig. 2. Serum concentration time course of p-cresylglucuronide in rats
with normal () and decreased () renal function after intravenous
injection of p-cresol (10 mg/kg). *P  0.05 vs. normal renal function.
units (FU), respectively] (Fig. 2). Here also, values in
rats with decreased renal function remained higher than
in rats with normal renal function from minute 30 onward
(P  0.05) (Fig. 2).
Urinary excretion
Creatinine and p-cresol. Table 2 shows the urinary
excretion of creatinine and p-cresol in rats with normal
and decreased renal function after the injection of creati-
nine, p-cresol, or an equivalent amount of isotonic saline
(control group for rats with decreased renal function).
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Table 2. Effect of renal failure on the excreted amount of unchanged p-cresol and creatinine in the urine of rats
over a period of four hours
Normal renal function Decreased renal function
Creatinine-treated p-cresol–treated Control Creatinine-treated p-cresol–treated
(N  8) (N  9) (N  7) (N  7) (N  8)
Creatinine mg 16.694.09 1.580.42 1.540.95 7.971.53a 2.001.71
p-cresol mg DL 0.6480.284 0.0160.013 0.0190.009a 0.1820.211a
a P  0.05 vs. normal renal function, similar treatment; DL, detection limit, 0.002 mg/L
Fig. 3. Cumulative urinary excretion of creatinine () and unmodified
p-cresol () in rats with normal (solid line) and decreased (dashed
line) renal function expressed as percent of the administered dose. *P
0.05 vs. normal renal function. In rats with normal and decreased renal
function both, cumulative creatinine excretion was each time more
substantial than that of unchanged p-cresol (P  0.05).
Urine of creatinine injected rats with normal renal func-
tion only contained an amount of p-cresol below its de-
tection limit. Urine of control and creatinine-injected
rats with decreased renal function also contained minor
and comparable amounts of p-cresol. Creatinine-injected
rats with decreased renal function excreted only half of
the amount of creatinine that was found in rats with
normal renal function receiving the same quantity of
creatinine (P 0.05); likewise, p-cresol–injected rats with
decreased renal function excreted only approximately
one-fourth the amount of p-cresol found in rats with
normal renal function receiving the same quantity of
p-cresol (P  0.05). Furthermore, the amount of creati-
nine found in the urine of p-cresol–injected rats was
comparable to that obtained in control rats with de-
creased renal function (Table 2).
After subtraction of the endogenously excreted
amounts of creatinine, 92.7  23.3% of the initially ad-
ministered amount was recovered in the urine of rats
with normal renal function in contrast to only 44.3 
8.5% in animals with decreased renal function (P 0.05)
(Fig. 3). Likewise, 21.0  10.0% of the injected amount
of p-cresol was excreted unchanged in the urine of rats
Fig. 4. Cumulative excretion of the sum of unchanged p-cresol and
p-cresylglucuronide (expressed as equivalent amounts of p-cresol) in
the urine of rats with normal () and decreased () renal function.
*P  0.05 vs. decreased renal function.
with normal renal function, whereas only 6.7  7.5% of
the administered dose was recovered in the urine of animals
with decreased renal function (P  0.05) (Fig. 3).
Hydrolysis of urinary p-cresylglucuronide and linear
regression analysis. Linear regression analysis between
the p-cresylglucuronide peak height before enzyme treat-
ment with -glucuronidase (pCG) on the one hand, and
the increase of the p-cresol peak after the enzyme treat-
ment (DpC) on the other hand, provided us with the
equation DpC  8.21*pCG  281 (N  3, r2  0.99),
which had a similar slope as the one found for rats with
normal renal function [27].
We calculated that in rats with decreased renal func-
tion, 0.96  0.76 mg of p-cresol was excreted in urine
as its glucuronide, in contrast to 1.82  0.75 mg in rats
with normal renal function (P  0.05). The excretion of
unchanged p-cresol, together with its glucuronide (ex-
pressed as equivalent amounts of p-cresol), again was
lower in rats with decreased renal function throughout
the experiment than in rats with normal renal function
(P  0.05) (Fig. 4). In total, 38.5  32.1% of the initially
administered p-cresol was recovered in the urine of rats
with decreased renal function, compared to 81.8 31.1%
in rats with normal renal function (P  0.05) (Fig. 4).
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Table 3. Effect of renal failure on the pharmacokinetic parameters of p-cresol and creatinine in rats injected
with p-cresol (10 mg/kg) or creatinine (60 mg/kg)
Creatinine p-cresol
Normal Decreased Normal Decreased
Parameter renal function renal function renal function renal function
K 1/h 0.840.09 0.110.03b 0.580.23a 0.060.03a,b
t1/2 h 0.80.1 6.61.7b 1.40.7a 11.70.4b
AUC0-240 mg/min/mL 6.500.49 17.883.57b 0.420.07 0.800.24b
Vd L/kg 0.60.1 0.60.1 2.81.2a 2.30.5a
Abbreviations are: K, elimination time constant; t1/2, half-life; AUC, area under the concentration time curve; Vd, volume of distribution.
a P  0.05 vs. creatinine; bP  0.05 vs. normal renal function
Fig. 5. Total (CLt), renal (CLr), and non-renal (CLnr) clearance of
creatinine (A ) and p-cresol (B ) in rats with normal vs. decreased renal
function. *P  0.05 vs. normal renal function; P  0.05 vs. CLt; P 
0.05 vs. CLr; P  0.05 vs. creatinine.
Kinetic parameters
The effect of renal failure on the kinetic parameters
of creatinine and p-cresol in rats is shown in Table 3
and Figure 5. For both creatinine and p-cresol, a higher
elimination rate constant and shorter half-life was ob-
served in rats with normal renal function compared to
rats with decreased renal function (P  0.05). For both
compounds, the AUC0-240 was at least twice as high in
rats with decreased renal function, compared to rats with
normal renal function (P  0.05) (Table 3). Total clear-
ances were much lower in rats with decreased renal func-
tion than in rats with normal renal function (P  0.05)
(Fig. 5). For creatinine, CLt and CLr were similar, as well
in rats with normal renal function as in rats with de-
creased renal function, each time resulting in a CLnr
near to 0 (Fig. 5A). In contrast, for p-cresol, CLt was
considerably higher than CLr (P  0.05) (Fig. 5B). In
rats with decreased renal function, CLnr was markedly
lower than in rats with normal renal function (P 0.05).
Finally, renal failure did not change the Vd of creatinine
and p-cresol (Table 3).
In rats with normal and decreased renal function both,
the elimination rate constant was higher for creatinine
than for p-cresol (P  0.05). Consequently, the corre-
sponding half-life was shorter for creatinine than for
p-cresol (P  0.05) (Table 3). Whereas in rats with nor-
mal and decreased renal function both, CLt was consider-
ably lower for creatinine than for p-cresol (P  0.05),
values for CLr were higher for creatinine (P  0.05)
each time (Fig. 5). Finally, in both rats with normal and
decreased renal function, Vd of p-cresol was several times
larger than that of creatinine (5 and 4 times, respectively)
(P  0.05) (Table 3).
DISCUSSION
The present study compares the kinetic characteristics
of creatinine and p-cresol in rats with normal and de-
creased renal function. Up to now, very few, if any,
studies have investigated the kinetic behavior of uremic
toxins, although such information might be useful for
the application of dialytic or other removal strategies.
Our results principally show that: (1) the volume of dis-
tribution of p-cresol in rats with decreased renal function
is approximately 4 times higher than that of creatinine,
which is essentially distributed in the body water; (2)
for both creatinine and for p-cresol, renal failure does not
change the volume of distribution; (3) for both creatinine
and for p-cresol, total and renal clearance are substan-
tially decreased in rats with decreased renal function
compared to rats with normal renal function; (4) whereas
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for p-cresol non-renal clearance is also substantially de-
creased, there is no non-renal clearance for creatinine;
and (5) p-cresylglucuronide, one of the main metabolites
of p-cresol, is eliminated much slower from the serum
in rats with renal failure.
For the completeness of our report, we would like to
emphasize that extrapolation to the human condition
might not always be possible, due to differences among
species. However, certain observations in uremic pa-
tients can be explained by the present results.
p-Cresol has a large volume of distribution (Table 3),
pointing to a multicompartmental behavior of this com-
pound. As a result, p-cresol removal is limited by inter-
mittent hemodialysis, as reported previously [7]. In a similar
context, Costigan and Lindup [32] reported that 3-carboxy-
4-methyl-5-propyl-2-furanpropionic acid (CMPF), another
strongly protein-bound uremic retention compound, was
hardly removed by hemodialysis and that over a pro-
longed period, this compound probably accumulates in
tissue and fat due to its lipophilic character. This might
create a reservoir, chronically maintaining enhanced
concentrations in the uremic condition. Therefore, espe-
cially if the biotransformation process of p-cresol is in-
fluenced by renal failure, it would be interesting to con-
sider removing this lipophilic compound by concepts
other than the traditional dialytic systems.
On top of difficult removal during the dialysis session,
a multicompartmental distribution might cause a more
important post-dialytic rebound. Consequently, the de-
crease in concentration during dialysis can be annihilated
to a large extent in the hours following the session. Pre-
liminary data from our group indeed show a substantial
rebound, neutralizing up to 50% of the intra-dialytic
decrease for p-cresol in the hours following dialysis. In
this regard, alternative dialytic time frames might offer
a solution for this problem. In a recent study, a decrease
of pre-dialytic p-cresol levels could be observed with
daily hemodialysis [33].
Another way to remove p-cresol could be to use adsor-
bents, either in extracorporeal devices for plasma treat-
ment, or as intestinally administered compound. The
efficiency of AST-120 in removing protein-bound sub-
stances such as indoxyl sulfate from the blood of dialysis
patients has been demonstrated [34–37] and a decrease
in the serum p-cresol concentration has also been re-
ported in rats treated orally with this adsorbent [38].
Alternative dialytic processes such as protein-leaking
dialysis strategies (protein leaking hemodialysis) [39]
or continuous ambulatory peritoneal dialysis (CAPD)
[40, 41], or low-efficiency continuous strategies (again
CAPD) [40, 41] should also be considered.
In parallel to our observations on rats with normal
renal function [27, 28], serum and urine in the present
experiments both contained p-cresylglucuronide after in-
travenous injection of p-cresol. According to our data,
the renal elimination of p-cresylglucuronide is disturbed
in renal failure (Fig. 4). At this point, however, we cannot
estimate the pathophysiologic impact of its accumula-
tion, but as far as we know, there are no arguments in
favor of its toxicity. The question can be raised, however,
whether retention of p-cresylglucuronide in the plasma
can make the glucuronidation reaction shift in the oppo-
site direction, resulting in an increase of the p-cresol
concentration, or at least a decrease in its metabolism.
Likewise, glucuronides might be hydrolyzed to a certain
extent, resulting in the regeneration of the parent com-
pound, hence generating a decrease in its CLt [42].
The importance of the kidneys in the elimination of
p-cresol is illustrated in Figure 3. At the end of the ex-
periment, the serum concentration of p-cresol was still
markedly higher in rats with decreased renal function
injected with p-cresol than in similarly treated rats with
normal renal function. In this context, Table 3 and Figure
2 also show that urinary excretion of unchanged p-cresol
in rats with normal renal function injected with p-cresol
was approximately 4 times higher than in their uremic
counterparts.
Interestingly, the comparable percentage of decrease
in CLt and CLr of p-cresol in rats with normal and de-
creased renal function suggests that renal failure not only
influences renal, but also non-renal clearance of p-cresol.
Similar decreases in non-renal clearance have been dem-
onstrated in rats with decreased renal function for the
intravenously injected drug diflunisal [42]. This decrease
in non-renal clearance indicates an inhibition of biotrans-
formation, either by blocking metabolism, or by compe-
tition of other retained compounds with metabolism by
the liver or other organs where enzymatic transport
mechanisms are overwhelmed, at least to a certain de-
gree. In any way, our data suggest that removal processes
other than CLr might be inhibited by the uremic status.
This observation again stresses the need for additional
strategies other than dialysis procedures to substantially
decrease the levels of p-cresol in uremia.
Biotransformation, either into a compound that is re-
moved more easily or into a compound that is less toxic,
as a way to remove uremic solutes, has up to now been
insufficiently explored. For homocysteine, demethyl-
ation, resulting in a return to the mother compound
methionine, is stimulated by administration of folic acid
and vitamin B6 [43, 44]. It remains open for discussion
whether a similar effect could be obtained for p-cresol
by enhancing its glucuronidation. Drugs such as pheno-
barbital have been demonstrated to enhance the gluc-
uronidation process [45], but the clinical usefulness of
such an approach remains as yet debatable. In addition,
if uremic retention hampers non-renal clearance, as is
suggested by the present data (Fig. 5), removal of the
responsible compound(s) might re-instate normal non-
renal removal processes. For this to occur, the responsi-
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ble compounds should, however, first be identified. Of
note, in a study by van Tellingen et al [46], the application
of superflux hemodialysis resulted in a decline of the
homocysteine concentration, although the removal by
the dialytic process, per se, remained unaltered. These
data also corroborate the hypothesis that removal of
compounds blocking metabolism possibly decreases sol-
ute concentration in the long term.
Tubular secretion of creatinine accounts for approxi-
mately 10% of its CLr [47, 48], adding this way of removal
to the one resulting from glomerular filtration. For
p-cresol, specific information about tubular handling is
to our knowledge not available. However, for other pro-
tein-bound compounds, such as CMPF [32], para-amino
hippurate [49], and the drugs mycophenolate mofetil [50]
and pravastatin [51], tubular secretion has been reported
to be substantial. If we extrapolate these observations
to the strongly protein-bound p-cresol, the substantial
loss of CLr observed in rats with decreased renal function
could be caused by an important decrease in tubular
secretion. However, to substantiate this line of thought,
further experiments should be performed by inhibiting
the tubular secretion (e.g., with probenecid or cimeti-
dine) [32, 47].
Finally, it is of note that an acute injection of p-cresol
was used in our experiments. It is possible that this com-
pound behaves differently in patients with end-stage renal
disease, chronically exposed to the toxin. We therefore
plan to do future experiments with chronic injections of
p-cresol.
CONCLUSION
P-cresol has a large volume of distribution which is
not influenced by experimental renal failure. Both renal
and total clearance of creatinine and p-cresol are mark-
edly affected in rats with decreased renal function. Fur-
thermore, we have demonstrated that non-renal clear-
ance of p-cresol is also disturbed in uremia. Finally, the
elimination from the serum of p-cresylglucuronide,
which is the main metabolite of p-cresol in the rat, is
also much slower in rats with renal failure.
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